GlassScriptPhysician profile
Andreas R Ward
NPI 1891064176
$3,082.86
in general payments reported to CMS, 2019-2025
35 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,003 · 2022: $826 · 2023: $567 · 2024: $484 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.59 | 2021-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $292.71 | 2021-2023 | |
| Astellas Pharma US INC | $253.80 | 2021-2025 | Veozah |
| Lilly USA, LLC | $213.56 | 2021-2024 | Mounjaro, Kisunla |
| Pfizer INC. | $191.32 | 2021-2025 | |
| Abbvie INC. | $188.82 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.41 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $112.69 | 2022-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $107.04 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $100.86 | 2021-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $91.03 | 2022-2024 | |
| Avanir Pharmaceuticals, INC. | $87.77 | 2021 | |
| Global Blood Therapeutics, INC. | $78.61 | 2021-2022 | |
| Eisai INC. | $77.20 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $77.15 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $75.48 | 2021-2023 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $55.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $53.39 | 2023 | Nuedexta, Rexulti |
| Sunovion Pharmaceuticals INC. | $51.31 | 2022 | |
| Neurelis, INC. | $39.83 | 2022-2024 | Valtoco |
| Phathom Pharmaceuticals, INC. | $37.43 | 2025 | Voquezna |
| Corcept Therapeutics | $36.83 | 2023 | Korlym |
| Janssen Pharmaceuticals, INC | $32.95 | 2021-2022 | |
| Ucb, INC. | $32.49 | 2025 | Nayzilam |
| Lundbeck LLC | $29.43 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $27.94 | 2022 | |
| Merck Sharp & Dohme LLC | $26.37 | 2021 | |
| Urovant Sciences INC | $24.34 | 2021 | |
| Daiichi Sankyo INC. | $23.43 | 2021 | |
| Aimmune Therapeutics, INC. | $22.83 | 2024 | |
| Genzyme Corporation | $20.01 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.82 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $16.24 | 2023 | Austedo |
| Amgen INC. | $15.32 | 2025 | Repatha, Otezla |
| Emmaus Medical, INC. | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.